Life-Threatening Hyperkalemia in Diabetic Kidney Disease

Intravenous calcium stabilizes the cardiac membrane and is the immediate priority when hyperkalemia causes ECG toxicity. It does not lower serum potassium, so shifting and removal must follow.

Spironolactone reduces aldosterone-mediated potassium excretion, while trimethoprim acts like amiloride at the distal nephron. Advanced CKD markedly increases susceptibility.

Insulin shifts potassium into cells and lowers serum concentration temporarily. Total body potassium remains elevated, so rebound hyperkalemia is possible without elimination.

Persistent or recurrent severe hyperkalemia with ECG toxicity despite initial therapy is a classic indication for urgent renal replacement therapy assessment.

Remove reversible contributors and reassess the balance between cardiorenal benefit and hyperkalemia risk. Reintroduction of beneficial therapy may be possible with structured monitoring and mitigation.